These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 14676632)

  • 21. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.
    Linette GP; Zhang D; Hodi FS; Jonasch EP; Longerich S; Stowell CP; Webb IJ; Daley H; Soiffer RJ; Cheung AM; Eapen SG; Fee SV; Rubin KM; Sober AJ; Haluska FG
    Clin Cancer Res; 2005 Nov; 11(21):7692-9. PubMed ID: 16278389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
    Yang S; Linette GP; Longerich S; Haluska FG
    J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.
    Baba T; Sato-Matsushita M; Kanamoto A; Itoh A; Oyaizu N; Inoue Y; Kawakami Y; Tahara H
    J Transl Med; 2010 Sep; 8():84. PubMed ID: 20843377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.
    Ginsberg BA; Gallardo HF; Rasalan TS; Adamow M; Mu Z; Tandon S; Bewkes BB; Roman RA; Chapman PB; Schwartz GK; Carvajal RD; Panageas KS; Terzulli SL; Houghton AN; Yuan JD; Wolchok JD
    Clin Cancer Res; 2010 Aug; 16(15):4057-65. PubMed ID: 20647477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination.
    Speiser DE; Baumgaertner P; Barbey C; Rubio-Godoy V; Moulin A; Corthesy P; Devevre E; Dietrich PY; Rimoldi D; Liénard D; Cerottini JC; Romero P; Rufer N
    J Immunol; 2006 Jul; 177(2):1338-48. PubMed ID: 16818795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.
    Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
    J Immunol Methods; 2000 Oct; 244(1-2):59-67. PubMed ID: 11033019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.
    Appay V; Speiser DE; Rufer N; Reynard S; Barbey C; Cerottini JC; Leyvraz S; Pinilla C; Romero P
    Eur J Immunol; 2006 Jul; 36(7):1805-14. PubMed ID: 16761313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.
    Asai T; Storkus WJ; Whiteside TL
    Clin Diagn Lab Immunol; 2000 Mar; 7(2):145-54. PubMed ID: 10702485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
    Speiser DE; Liénard D; Pittet MJ; Batard P; Rimoldi D; Guillaume P; Cerottini JC; Romero P
    Eur J Immunol; 2002 Mar; 32(3):731-41. PubMed ID: 11870617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
    Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
    J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.
    Dhodapkar MV; Young JW; Chapman PB; Cox WI; Fonteneau JF; Amigorena S; Houghton AN; Steinman RM; Bhardwaj N
    Clin Cancer Res; 2000 Dec; 6(12):4831-8. PubMed ID: 11156242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients.
    Castelli C; Mazzocchi A; Rini F; Tarsini P; Rivoltini L; Maio M; Gallino G; Belli F; Parmiani G
    Eur J Immunol; 1998 Apr; 28(4):1143-54. PubMed ID: 9565353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy.
    Bredenbeck A; Losch FO; Sharav T; Eichler-Mertens M; Filter M; Givehchi A; Sterry W; Wrede P; Walden P
    J Immunol; 2005 Jun; 174(11):6716-24. PubMed ID: 15905511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
    Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
    Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
    Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
    Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.
    Phan GQ; Touloukian CE; Yang JC; Restifo NP; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; White DE; Rosenberg SA
    J Immunother; 2003; 26(4):349-56. PubMed ID: 12843797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
    Rosenberg SA; Sherry RM; Morton KE; Scharfman WJ; Yang JC; Topalian SL; Royal RE; Kammula U; Restifo NP; Hughes MS; Schwartzentruber D; Berman DM; Schwarz SL; Ngo LT; Mavroukakis SA; White DE; Steinberg SM
    J Immunol; 2005 Nov; 175(9):6169-76. PubMed ID: 16237114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells.
    Kawashima I; Tsai V; Southwood S; Takesako K; Celis E; Sette A
    Int J Cancer; 1998 Nov; 78(4):518-24. PubMed ID: 9797143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.